Pyxis Oncology (PYXS) Stock Overview
A clinical stage company, engages in the development of therapeutics to treat solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PYXS Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Pyxis Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.00 |
| 52 Week High | US$5.55 |
| 52 Week Low | US$0.97 |
| Beta | 1.43 |
| 1 Month Change | 17.65% |
| 3 Month Change | 30.72% |
| 1 Year Change | 73.91% |
| 3 Year Change | -40.12% |
| 5 Year Change | n/a |
| Change since IPO | -84.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| PYXS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.7% | -4.9% | -1.0% |
| 1Y | 73.9% | 28.1% | 23.3% |
Return vs Industry: PYXS exceeded the US Biotechs industry which returned 28.1% over the past year.
Return vs Market: PYXS exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| PYXS volatility | |
|---|---|
| PYXS Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PYXS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PYXS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 56 | Tom Civik | www.pyxisoncology.com |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.
Pyxis Oncology, Inc. Fundamentals Summary
| PYXS fundamental statistics | |
|---|---|
| Market cap | US$120.05m |
| Earnings (TTM) | -US$81.73m |
| Revenue (TTM) | US$13.86m |
Is PYXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYXS income statement (TTM) | |
|---|---|
| Revenue | US$13.86m |
| Cost of Revenue | US$2.39m |
| Gross Profit | US$11.47m |
| Other Expenses | US$93.21m |
| Earnings | -US$81.73m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 82.77% |
| Net Profit Margin | -589.80% |
| Debt/Equity Ratio | 0% |
How did PYXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 22:36 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pyxis Oncology, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Bradley Canino | Guggenheim Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |